---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-135610"
form_type: "8-K"
ticker: "ZYME"
cik: "0001937653"
company_name: "Zymeworks Inc."
filed_at: "2026-04-01T23:59:59+00:00"
generated_at: "2026-05-15T08:01:39.934672+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Zymeworks appoints Kristin Stafford as CFO, effective April 1, 2026

## Summary
- Stafford previously SVP, CAO at Royalty Pharma; brings life sciences capital markets experience.
- Compensation includes $520K annual base salary, 45% target bonus, $52K signing bonus.
- Equity awards: 178K options, 119K RSUs (4-year vest), and 50K RSUs (3-year vest).
- Kenneth Galbraith ceases as interim CFO but remains CEO and Chairman of the Board.

## SEC filing metadata
- accession: 0001193125-26-135610
- form_type: 8-K
- ticker: ZYME
- cik: 0001937653
- company_name: Zymeworks Inc.
- filed_at: 2026-04-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937653/000119312526135610/0001193125-26-135610-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937653/000119312526135610/d142598d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-135610
- JSON: https://secwatch.observer/filing/0001193125-26-135610.json
- Plain text: https://secwatch.observer/filing/0001193125-26-135610.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.